View printer-friendly version
« Back
July 17, 2018 8:30 a.m.
Teva Highlights Key Milestones Achieved in the 2017 Social Impact Report

JERUSALEM--(BUSINESS WIRE)--Jul. 17, 2018-- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) published its annual social impact report, highlighting achievements related to the two pillars that drive the Company’s initiatives: building healthy communities and leading a responsible business.

Teva’s 2017 Social Impact Report spotlights the company’s commitment to corporate responsibility and transparency, and provides context on its efforts to contribute to healthy communities in ways the business can uniquely support—through safe medicines, collaboration, health initiatives and innovative research. The report also presents six new corporate positions and policies, establishing the company’s commitment to donations, human rights, diversity and inclusion, occupational health and safety, the environment and antimicrobial resistance.

“Since joining the company late last year, I have been motivated by the opportunity to advance our legacy of promoting health. Operating as an ethical, enduring enterprise is critical to continue bringing value to our business, our stakeholders and society,” said Kåre Schultz, President and CEO of Teva. “Social Impact is inherently embedded in our brand, as Teva is uniquely positioned to improve health by offering accessible treatments to millions worldwide.”

Teva also outlined progress on its signature initiative to address the challenges of non-communicable diseases by uncovering solutions to multiple chronic conditions (MCC) with the release of an independent research report, Multiple Chronic Conditions: The Global State, in 2017. The report quantifies health, economic and personal challenges of patients with MCC and the burden on communities and systems.

“We are continuing to focus on engagement with patients, caregivers and communities, ensuring we communicate with them in a cohesive way, and this is a central element of our social impact efforts,” said Iris Beck-Codner, Teva’s Executive Vice President, Global Brand & Communications. “These activities bring our new brand promise to life, enabling people to live better days, and support our goal to make the world a healthier place.”

Contributing to healthy communities

As part of Teva’s ongoing efforts to contribute to healthy communities in 2017, Teva invested $1.8B in R&D, contributed $82.3M across more than 25 countries through donations, patient assistance and community involvement, and funded more than $350,000 of research on genetic disorders and autism brain mechanisms. Additional efforts included the support of 80 patient programs in 38 countries, reaching more than 300,000 people and convening 17 patient groups via the Improving Health Global Patient Advocacy Dialogue. Finally, Teva assembled global health leaders to discuss potential solutions to MCC at the World Economic Forum Sustainable Development Impact Summit.

Leading a responsible business

Teva has conducted its business with integrity through investments such as $120M in a global program to make medicines at 38 facilities counterfeit-compliant ahead of anticipated regulatory changes, and a $20.3M investment in 87 energy-efficiency projects, which yielded annualized electricity savings, while reducing greenhouse gas emissions by 16,700 tons.

Carlo de Notaristefani, Teva’s Executive Vice President, Global Operations, added, “For Teva, social impact is rooted in responsible business and manufacturing practices. This work includes ensuring transparency and compliance in our operations, protecting the environment and supporting our employees and the places we call home. It also encompasses efforts focused on improving patient lives and increasing access to healthcare, working together with partners across sectors.”

To view the 2017 Social Impact Report, visit here or to learn more about Teva’s Social Impact efforts online, click here.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

  • our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights;
  • our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
  • our business and operations in general, including: failure to effectively execute the restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
  • compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
  • other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov and www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Source: Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.
IR Contacts
United States
Kevin C. Mannix, 215-591-8912
or
Israel
Ran Meir, 972 (3) 926-7516
or
Tomer Amitai, 972 (3) 926 7656
PR Contacts
United States

Elizabeth DeLuca, 267-468-4329
or
Israel
Yonatan Beker, 972 (54) 888 5898